Home pageBHC • NYSE
add
Valeant Pharmaceuticals
8,16Â $
After Hours:(0,00%)0,00
8,16Â $
Data e ora chiusura: 7 ott, 16:00:27 GMT-4 · USD · NYSE · Disclaimer
Chiusura precedente
8,32Â $
Intervallo giornaliero
8,08Â $ - 8,32Â $
Intervallo annuale
3,96Â $ - 11,46Â $
Cap di mercato
2,95Â Mrd USD
Volume medio
2,65Â Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Entrate | 2,40Â Mrd | 10,89% |
Spese di gestione | 1,26Â Mrd | 10,91% |
Utile netto | 10,00Â Mln | -61,54% |
Margine di profitto netto | 0,42 | -65,00% |
Utili per azione | 0,98 | 21,83% |
EBITDA | 741,00Â Mln | 6,47% |
Aliquota fiscale effettiva | 102,08% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 595,00Â Mln | 2,76% |
Totale attivo | 26,50Â Mrd | 3,89% |
Totale passivo | 26,72Â Mrd | 5,91% |
Patrimonio netto totale | -227,00 Mln | — |
Azioni in circolazione | 367,10 Mln | — |
Prezzo/valore contabile | -2,60 | — |
Redditività dell'attivo | 3,96% | — |
Rendimento sul capitale | 4,88% | — |
Flusso di cassa
Flusso di cassa netto
(USD) | giu 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 10,00Â Mln | -61,54% |
Liquidità di esercizio | 380,00 Mln | 84,47% |
Contanti da investimenti | -79,00Â Mln | -163,33% |
Contanti da finanziamenti | -424,00Â Mln | -253,33% |
Flusso di cassa netto | -132,00Â Mln | -331,58% |
Flusso di cassa libero | 431,62Â Mln | 72,13% |
Informazioni
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
CEO
Fondazione
1959
Sito web
Dipendenti
20.270